Status:

COMPLETED

A Pharmacokinetic Analysis of Levetiracetam Prophylaxis in Critically Ill Patients With Severe Traumatic Brain Injury

Lead Sponsor:

University of Cincinnati

Collaborating Sponsors:

American College of Clinical Pharmacy

Conditions:

Traumatic Brain Injury

Eligibility:

All Genders

18-75 years

Brief Summary

This study aims is to describe the pharmacokinetic properties of levetiracetam through measurement of serum concentrations in critically ill, severe traumatic brain injury patients.

Detailed Description

Levetiracetam (LEV) is widely used for the prevention and treatment of seizures given its favorable pharmacokinetic profile. A strong correlation between serum concentrations and clinical efficacy has...

Eligibility Criteria

Inclusion

  • Admitted to the neurosurgical intensive care unit or surgical intensive care unit following severe traumatic brain injury (post-resuscitation GCS 3-8 with or without CT abnormalities)
  • Receiving intravenous levetiracetam for seizure prophylaxis at a dose of 1000 mg every 12 hours or 1000 mg every 8 hours at time of enrollment

Exclusion

  • Known history of epilepsy or seizure disorder
  • Taking antiseizure medication prior to admission
  • Taking medication with known effect on levetiracetam pharmacokinetics including carbamazepine, phenytoin, oxcarbazepine, mefloquine, methotrexate, mianserin, or orlistat
  • Weight \< 50 kg
  • Anticipated survival \<72 hours from injury, as deemed by the primary neurosurgical provider
  • Acute Kidney Injury (Scr rise \> 0.3 mg/dL from baseline) or creatinine clearance \<50 mL/min at time of enrollment
  • Prisoners
  • Pregnant

Key Trial Info

Start Date :

January 1 2021

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

October 1 2023

Estimated Enrollment :

10 Patients enrolled

Trial Details

Trial ID

NCT04836481

Start Date

January 1 2021

End Date

October 1 2023

Last Update

February 29 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Cincinnati Medical Center

Cincinnati, Ohio, United States, 45219

A Pharmacokinetic Analysis of Levetiracetam Prophylaxis in Critically Ill Patients With Severe Traumatic Brain Injury | DecenTrialz